Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer

Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

1988 • 2,196 citations

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

1994 • 522 citations

Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

1975 • 434 citations

Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes

1977 • 337 citations

Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.

1986 • 255 citations

Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

1988 • 239 citations

Effect of Cyclophosphamide on Immunological Control Mechanisms

1982 • 236 citations

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

1987 • 224 citations

Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity

1974 • 209 citations

Antibodies Against Mucin-Associated Sialyl-Tn Epitopes Correlate with Survival of Metastatic Adenocarcinoma Patients Undergoing Active Specific Immunotherapy with Synthetic STn Vaccine

1996 • 184 citations

Enhancing the Effect of THERATOPE STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide

1996 • 155 citations

Enhancement of Dinitrochlorobenzene (DNCB) Contact Sensitization by Cyclophosphamide in the Guinea Pig**From the Department of Dermatology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104.

1967 • 133 citations

Vaccine therapy for malignant melanoma

1996 • 133 citations

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.

1997 • 128 citations

Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice.

1979 • 120 citations

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer

1996 • 105 citations

Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.

1981 • 100 citations

Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells

1990 • 98 citations

Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans

1997 • 92 citations

Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.

1980 • 92 citations

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

1992 • 89 citations

Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.

1990 • 75 citations

Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.

1987 • 66 citations

Immunogenicity of a polyvalent melanoma antigen vaccine in humans

1988 • 62 citations

Relative susceptibilities of T cell subsets involved in delayed-type hypersensitivity to sheep red blood cells to the in vitro action of 4-hydroperoxycyclophosphamide.

1980 • 61 citations

Polyvalent Melanoma Vaccine Improves Survival of Patients with Metastatic Melanomaa

1993 • 60 citations

Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells.

1996 • 55 citations

Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma.

1986 • 54 citations

Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer.

1984 • 53 citations

Phase III trial of melacine?? melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma

1997 • 46 citations

A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma

1977 • 37 citations

Transforming growth factor-?-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy

1994 • 37 citations

Suppressor cell activity in melanoma patients. I. Relation to tumor growth and immunoglobulin levels in vivo

1981 • 33 citations

Active specific immunization in the treatment of patients with melanoma.

1996 • 26 citations

Active specific immunotherapy of melanoma

1995 • 25 citations

Update on active specific immunotherapy with melanoma vaccines

1997 • 25 citations

Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.

1988 • 17 citations

Potentiation of Antitumor CTL Response by GM-CSF Involves a B7-Dependent Mechanism

1997 • 10 citations